Rare diseases
Investigational molecules
Locations
Nadrazni 3368/30a, Smichov, 150 00 Prague, Czechia
Praglandia s.r.o. in Prague, Czechia specialises in clinical trials of conditions such as Dermatitis atopic, Psoriasis, Major depression, Migraine, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in Type 2 Diabetes and related metabolic disorders, focusing on innovative treatments that address both obesity and cardiovascular diseases. The center's work in this area aims to improve patient outcomes by exploring alternatives to traditional insulin therapies.
Through its research, the center contributes to the development of therapies that are not only effective but also enhance the quality of life for patients with complex metabolic conditions.
Specializing in atopic dermatitis and other skin conditions, the center is pioneering studies that evaluate the efficacy and safety of novel treatments. This includes the use of advanced biologics and other therapeutic agents to manage moderate-to-severe cases.
The center's research efforts are instrumental in developing new standards of care for dermatological conditions, offering hope for improved management and patient satisfaction.
Focusing on migraine management, the center is engaged in cutting-edge research to find effective preventive treatments for patients who have not responded to existing therapies. This includes exploring new pharmacological options that aim to reduce the frequency and severity of migraine episodes.
By advancing the understanding of migraine pathophysiology, the center is paving the way for innovative solutions that can significantly improve the lives of those affected by this debilitating condition.
The center is dedicated to enhancing the treatment of Major Depressive Disorder through research on adjunctive therapies. By investigating the long-term safety and efficacy of novel antidepressant combinations, the center aims to provide more effective treatment options for patients with treatment-resistant depression.
These efforts are crucial in addressing the unmet needs in mental health care, offering new hope for individuals struggling with persistent depressive symptoms.
Clinical trials currently enrolling participants at this site.
Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
CzechiaLong-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis
CzechiaStudy of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
CzechiaStudy of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
CzechiaStudy of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
CzechiaStudy of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis
CzechiaEffect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)
CzechiaLong‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis
CzechiaA study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease
CzechiaA Study of fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.
CzechiaSafety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder
CzechiaStudy of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants
CzechiaMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
